ALTIMMUNE, INC. (NASDAQ:ALT) Files An 8-K Other Events
Item8.01
| Other Events |
On May16, 2017, Altimmune, Inc. (the Company) announced the
appointment of Sybil Tasker, M.D., FACP, FIDSA, the Companys
Senior Vice President of Clinical Research and Development, as
the Companys Chief Medical Officer. A copy of the Companys press
release announcing Dr.Taskers appointment as Chief Medical
Officer is attached hereto as Exhibit 99.1.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
ExhibitNo. |
Description of Exhibit |
|
|
99.1 |
Press release dated May 16, 2017 |
2
About ALTIMMUNE, INC. (NASDAQ:ALT)
Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn. NasoVAX is an intranasally administered recombinant influenza vaccine. The Company has completed Phase I clinical trials of NasoVAX. HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus. NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape. ALTIMMUNE, INC. (NASDAQ:ALT) Recent Trading Information
ALTIMMUNE, INC. (NASDAQ:ALT) closed its last trading session down -0.02 at 5.55 with 129,003 shares trading hands.